CytoDyn Selects Waisman Facility to Manufacture DNA-based Preflu Vaccine
Product is said to offer an alternative approach to immunization.!--h2>
CytoDyn chose the Waisman Clinical BioManufacturing Facility at the University of Wisconsin at Madison to manufacture its DNA-based preflu vaccine. The company says the product provides an alternative approach to immunization that could make flu vaccines for the seasonal flu and bird flu more effective.
The vaccine uses DNA technology to implant a false memory of previous exposure to the flu virus, including the inactivated virus contained in standard vaccines.